Publications by authors named "I Zandvakili"
Background And Aims: Glucagon-like peptide-1 receptor agonists (GLP1RAs) can cause delayed gastric emptying, raising concern for retained gastric contents (RGCs) during endoscopy and adverse anesthesia events. We aimed to determine associations between GLP1RA and endoscopy and anesthesia outcomes.
Methods: This single-center retrospective cohort study examined patients prescribed GLP1RA who underwent outpatient endoscopy stratified by exposure at the time of endoscopy.
Despite sharing incretin activity with glucagon-like peptide 1 (GLP-1), the development of gastric inhibitory polypeptide (GIP)-based drugs has been hindered by the minor effects of native GIP on appetite and body weight and genetic studies associating loss-of-function with reduced obesity. Yet, pharmacologically optimized GIP-based molecules have demonstrated profound weight lowering benefits of GIPR agonism when combined with GLP-1-based therapies, which has re-energized deeper exploration of the molecular mechanisms and downstream signaling of GIPR. Interestingly, both GIPR agonism and antagonism offer metabolic benefits, leading to differing viewpoints on how to target GIPR therapeutically.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the association between a common variant of the MLXIPL gene, specifically Gln241His, and its impact on metabolic health, particularly regarding triglyceride levels and steatotic liver disease (SLD).
- Findings from two large biobanks indicate that individuals with this genetic variant often have lower triglyceride levels and certain liver enzymes but are at a higher risk for SLD, especially if they are female, obese, or carry another specific variant (PNPLA3 I148M).
- The results suggest that targeting the MLXIPL pathway could be a potential strategy for treating SLD and related conditions, but further research is required to understand the underlying mechanisms.
Background: The hepatoprotective effects of aspirin have been observed in individuals with viral hepatitis; however, its impact on the general population remains uncertain. Understanding the association between aspirin use and the development of liver diseases is crucial for optimizing preventive strategies.
Methods: We identified individuals with aspirin use in the UK Biobank and the Penn Medicine Biobank, as well as propensity-score-matched controls.